Childhood extraosseous osteosarcoma

Summary

Childhood extraosseous osteosarcoma (MONDO:0004176) is a disease. A subtype of extraosseous osteosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood extraosseous osteosarcoma
Mondo ID	MONDO:0004176
DOID	DOID:7297
NCIT	C27376
UMLS	C1332968
MedGen	232060
GARD	0023863
Is cancer (heuristic)	no

Also known as: childhood extraosseous osteosarcoma · childhood extraskeletal osteosarcoma · extraosseous osteosarcoma of childhood · paediatric extraosseous osteosarcoma · paediatric extraskeletal osteosarcoma · pediatric extraosseous osteosarcoma · pediatric extraskeletal osteosarcoma

Disease family

This is a subtype of extraosseous osteosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › osteosarcoma › extraosseous osteosarcoma › childhood extraosseous osteosarcoma

Related subtypes (6): kidney osteogenic sarcoma, mediastinal extraskeletal osteosarcoma, liver extraskeletal osteosarcoma, breast extraskeletal osteosarcoma, adult extraskeletal osteosarcoma, central nervous system extraskeletal osteosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.